Blog Posts

DOSE OF REALITY: BIG PHARMA’S PATENT ABUSE BLOCKS COMPETITION IN THE PRESCRIPTION DRUG MARKET, KEEPS DRUG PRICES HIGH

May 21, 2024

Senate Hearing Offers Opportunity to Highlight Market-Based Solutions to Hold Read More

DOSE OF REALITY: STUDY FINDS NEARLY THREE-QUARTERS OF BIG PHARMA’S PATENTS ON TOP-SELLING DRUGS FILED AFTER FDA APPROVAL

May 16, 2024

Analysis Showcases Egregious Scale of Big Pharma’s Patent Thickets on Read More

DOSE OF REALITY: IQVIA REPORT SHOWS HOW BIG PHARMA’S EGREGIOUS PRICING PRACTICES DRIVE INCREASED PRESCRIPTION DRUG SPENDING

May 10, 2024

Analysis Shows Price Hikes Outpacing Inflation, Rising Launch Prices and Read More

BIG PHARMA EARNINGS WATCH: ELI LILLY, NOVO NORDISK, ABBVIE, AMGEN, GLAXOSMITHKLINE AND PFIZER

May 6, 2024

Repeated Price Hikes and Egregious Prices on GLP-1 Weight Loss Drugs Boost Read More

DOSE OF REALITY: BIOSIMILAR COMPETITION GENERATES SIGNIFICANT SAVINGS FOR PATIENTS AND THE U.S. HEALTH CARE SYSTEM

May 2, 2024

Reports Find Biosimilars Have Lower Prices Than Brand Name Biologics Read More

BIG PHARMA EARNINGS WATCH: NOVARTIS, MERCK, ASTRAZENECA, BRISTOL MYERS SQUIBB AND SANOFI

Apr 26, 2024

Big Pharma Continues Raking in Big Profits and Expectation-Beating Revenue Read More

DOSE OF REALITY: NEW ANALYSES UNDERSCORE HOW BIG PHARMA’S EGREGIOUS PRICING OF WEIGHT LOSS DRUGS IS UNSUSTAINABLE

Apr 25, 2024

Two Reports Explore Cost for U.S. Patients and the U.S. Health Care System of Read More

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Apr 19, 2024

Big Pharma Giant Kicks Off Q1 Earnings After Hiking Prices More Than 40 Times Read More

SECOND OPINION: BIG PHARMA’S OUT-OF-POCKET PLANS ON BRAND NAME INHALERS MAY BE DESIGNED TO FURTHER UNDERMINE COMPETITION

Apr 8, 2024

Big Pharma’s Announcements Designed to Deflect from Criticism and Scrutiny Read More

Dose of Reality: CBO Confirms Big Pharma’s Egregious Prices on Weight Loss Drugs Are Unsustainable

Mar 22, 2024

CBO Says Cost to Taxpayers of Covering GLP-1 Medications Would Outpace Savings Read More

THEN VS. NOW: PFIZER LATEST BIG PHARMA GIANT TO ACCIDENTALLY DEBUNK INDUSTRY’S OWN DOOM-AND-GLOOM INNOVATION RHETORIC

Mar 7, 2024

Big Pharma Exec Downplays “Modest” Drug Pricing Solutions That CEO Read More

BIG PHARMA WATCH: BIG PHARMA SET NEW RECORD FOR OUT-OF-CONTROL LAUNCH PRICES IN 2023, UP 35 PERCENT FROM PREVIOUS YEAR

Feb 26, 2024

Median Price Set by Brand Name Drug Makers on New Treatments Climbs to Read More